Roivant Sciences

Zest Health, LLC is a health technology company based in Chicago, Illinois, that focuses on transforming healthcare navigation through its mobile application. The app is designed for consumers, employers, and healthcare providers, featuring tools such as Talk to Me for immediate access to medical experts, Schedule Me for booking appointments, Inform Me for health information akin to WebMD, and Track Me for managing electronic health records. Founded in 2013, Zest Health aims to enhance access to healthcare professionals and support preventative care and disease management. In addition, Zest Dermatology, a subsidiary of Roivant, specializes in providing value-based virtual care for patients with conditions like eczema and psoriasis, partnering with health plans and employers to optimize dermatology care while minimizing specialty drug costs. By leveraging data-driven care models and collaborating with leading dermatologists, Zest Health strives to improve patient outcomes and streamline healthcare experiences.

Immunovant, headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with autoimmune diseases. Its primary focus is on developing monoclonal antibodies, notably IMVT-1401, a fully human antibody that targets the neonatal Fc receptor (FcRn). This investigational product is designed for subcutaneous injection and aims to address various IgG-mediated autoimmune conditions. IMVT-1401 is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials also initiated for warm autoimmune hemolytic anemia. Additionally, the company is developing batoclimab and IMVT-1402, both targeting FcRn.

Lokavant is an information technology company specializing in clinical trial intelligence. It provides real-time monitoring and anticipatory analytics to enhance the management of clinical trials. By leveraging advanced analytics and visualization techniques, Lokavant aims to facilitate rigorous analysis and proactive risk management, thereby simplifying the monitoring process for clinical trials. The company integrates artificial intelligence and human insights to deliver risk alerts and real-time visualizations, ensuring that stakeholders can make informed decisions throughout the trial lifecycle.

Medallion is a San Francisco-based company founded in 2020 by Derek Lo, specializing in a network management platform tailored for the healthcare industry. The company offers an all-in-one solution for licensing, credentialing, and payer enrollment, aimed at simplifying the often cumbersome processes associated with healthcare paperwork. Its platform provides features such as primary source verification, continuing medical education tracking, and document management, enabling healthcare providers and telemedicine companies to minimize time spent on administrative tasks and focus more on patient care.

Gen-t, established in 2021 and based in São Paulo, Brazil, operates a platform that serves as a comprehensive map of genomic research. The company specializes in developing a diverse genetic biobank, reflecting Brazil's ethnic diversity, to facilitate innovative research across various fields. By providing access to this rich genetic data, Gen-t aims to enhance biotechnology advancements and enable the creation of effective medicines tailored to Brazil's population.

Immunovant, headquartered in New York, is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with autoimmune diseases. Its primary focus is on developing monoclonal antibodies, notably IMVT-1401, a fully human antibody that targets the neonatal Fc receptor (FcRn). This investigational product is designed for subcutaneous injection and aims to address various IgG-mediated autoimmune conditions. IMVT-1401 is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials also initiated for warm autoimmune hemolytic anemia. Additionally, the company is developing batoclimab and IMVT-1402, both targeting FcRn.

Silicon Therapeutics is an innovative drug design and development company that utilizes a unique, physics-driven approach to advance biotechnology. By integrating computational methods with chemistry and biology research and development, the company aims to target previously deemed intractable protein targets for drug discovery. Its specialized platform leverages the innate immune system to simulate biological molecules according to physical laws, facilitating the prediction of interactions, energies, and conformational behaviors of drug targets. This technology provides a deeper understanding of the relationship between protein conformations and biological outcomes, positioning Silicon Therapeutics at the forefront of novel small molecule therapeutic development.

Datavant is a health data platform company focused on securely connecting and organizing biomedical data to support drug development and clinical trials. It provides a privacy-preserving network that enables the secure exchange of health records across thousands of organizations, helping researchers and pharmaceutical developers access real-world data while protecting patient privacy. By structuring data for trial design and interpretation, the company aims to improve clinical outcomes and accelerate medical research.

Patara Pharma, Inc., established in 2013 and headquartered in San Diego, California, is a clinical-stage biotechnology company dedicated to developing therapeutics targeting debilitating allergic and inflammatory diseases affecting orphan or focused patient populations. Its lead product candidate, PA101B, is an immune modulator with mast cell stabilizing properties designed for treating chronic cough refractory to existing therapies, including individuals with idiopathic pulmonary fibrosis, and for managing indolent systemic mastocytosis, an orphan indication.

Datavant is a health data platform company focused on securely connecting and organizing biomedical data to support drug development and clinical trials. It provides a privacy-preserving network that enables the secure exchange of health records across thousands of organizations, helping researchers and pharmaceutical developers access real-world data while protecting patient privacy. By structuring data for trial design and interpretation, the company aims to improve clinical outcomes and accelerate medical research.

Arbutus Biopharma Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing treatments for chronic hepatitis B virus (HBV) infection. The company has a comprehensive pipeline that includes AB-836, a capsid inhibitor designed to prevent HBV replication, and AB-423, currently in pre-clinical studies. Arbutus is also developing RNA interference (RNAi) therapeutics aimed at reducing hepatitis B surface antigen levels in infected patients. Notable candidates include AB-729, a second-generation RNAi therapeutic targeting liver cells, and an orally active HBV RNA destabilizer to promote RNA degradation. Additionally, Arbutus is conducting clinical trials and pre-clinical studies to evaluate its proprietary HBV therapies in combination with standard care treatments. The company engages in strategic alliances and collaborations to enhance its research and development efforts. Headquartered in Warminster, Pennsylvania, Arbutus Biopharma was formerly known as Tekmira Pharmaceuticals Corporation before rebranding in July 2015.